---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-026391"
form_type: "8-K"
ticker: "CTSO"
cik: "0001175151"
company_name: "Cytosorbents Corp"
filed_at: "2025-03-21T23:59:59+00:00"
generated_at: "2026-05-24T08:30:19.955058+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CytoSorbents reschedules earnings call to March 31; reaffirms Q4 product revenue $9.0-$9.2M (22-25% growth)

## Summary
- Earnings call rescheduled to March 31, 2025 at 4:30 PM ET; annual audit still in progress.
- Q4 product revenue expected $9.0-$9.2M (+22-25% YoY); full-year product revenue $35.4-$35.6M (+14% YoY).
- Q4 product gross margin ~70%, vs 61% prior quarter and 72% prior year.
- Pro-forma cash balance at Dec 31, 2024 ~$17.0M (unrestricted $15.5M); net Q4 cash burn ~$2.5M.
- DrugSorb-ATR marketing applications under FDA and Health Canada review; regulatory decisions expected in 2025.

## SEC filing metadata
- accession: 0001104659-25-026391
- form_type: 8-K
- ticker: CTSO
- cik: 0001175151
- company_name: Cytosorbents Corp
- filed_at: 2025-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175151/000110465925026391/0001104659-25-026391-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175151/000110465925026391/tm259948d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-026391
- JSON: https://secwatch.observer/filing/0001104659-25-026391.json
- Plain text: https://secwatch.observer/filing/0001104659-25-026391.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.